Check out BTA's latest preso, the seasonal market has jumped to blockbuster status.
The global medical community have been primed with education on anti-virals, and so have other large pharma. They can see plain and simple that the prescription market is blockbuster, and the quite separate stockpiling market is as well.
All this bodes well for the ROW license. I'm excited!
PS. It looks like LANI may already have gained a >20% market share in Japan. Great effort.
Check out BTA's latest preso, the seasonal market has jumped to...
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)